CD163 and neoplasm: A comparison of marker cluster densities of patients whose tumor subtypes differed between primary tumor and liver metastasis to those patients whose subtypes matched indicates that CD68+MMP9+ in the primary was lower (P = 0.034) in patients with differing ER subtype, whereas BCLM HIF1α+ and CD163+MMP9+ were lower (P = 0.014 and 0.032, respectively) and E-cad+ was higher (P = 0.018) in patients with differing HER2 subtype.